CLINICAL TRIAL AGREEMENT For Clinical Trials Conducted at the National Institutes of Health Clinical Center BETWEEN THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) AND Jasper Therapeutics, Inc. Protocol # 16-I-0032
Exhibit 10.30
***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit. ***
IND SPONSOR: NIAID
For Clinical Trials Conducted at the National Institutes of Health Clinical Center
BETWEEN
THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
(NIAID)
AND
Jasper Therapeutics, Inc.
Xxxxxxxx # 00-X-0000
High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease
Version 1.0
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), which is part of the United States Government Department of Health and Human Services (HHS), as represented by the Division of Intramural Research (DIR), and Jasper Therapeutics, Inc. (“Company”), located at 0000 Xxxxxx Xxxxxxx, Xxx. 000, Xxxxxxx Xxxx, XX 00000 (individually referred to as the “Party” and collectively referred to as the “Parties”) have agreed to cooperate in the conduct of a clinical trial at the NIH Clinical Center, in Bethesda, Maryland, designated as Protocol No. 16-1-0032 for JSP191, the title of which is “High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease.”
This Agreement sets forth the terms and conditions under which this Protocol will be conducted and the Clinical Trial will be managed.
The Company and the NIAID agree as follows:
| 1. | DEFINITIONS |
The terms listed in this Section have the meanings indicated throughout this Agreement. To the extent a definition of a term as provided in this Section is inconsistent with a corresponding definition in the applicable sections of either the United States Code (U.S.C.) or the Code of Federal Regulations (C.F.R.), the definition in the U.S.C. or C.F.R. will control.
“Adverse Event” (AE) means any untoward medical occurrence in a Human Subject to whom the Test Article has been administered or the definition as otherwise stated in the Protocol. An Adverse Event does not necessarily have a causal relationship with the Test Article, that is, it can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the Test Article, whether or not it is related to it. Adverse Event is further defined in ICH E6 section 1.2 and 21 C.F.R 312.32.
“Affiliates” means, with respect to the Company:
| (i) | any legal entity of which the securities or other ownership interests representing fifty per cent (50%) or more of the equity or fifty per cent (50%) or more of the ordinary voting power or fifty per cent (50%) or more of the general partnership interest are, at the time such determination is being made, owned, controlled or held, directly or indirectly, by such legal entity, or |
| (ii) | any legal entity which, at the time such determination is being made, is controlling or under common control with, such legal entity. |
As used in this definition, the term “control”, whether used as a norm or verb, refers to the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting securities, by contract or otherwise.
“Agreement” means this Clinical Trial Agreement or “CTA,” all executed amendments and supplements to this Agreement, and all schedules to this Agreement.
“Case Report Form” (CRF) means the data collection form(s) to be completed for each Human Subject participating in the Clinical Trial.
| Page 2 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
“Certificate of Confidentiality” (CoC) means a certificate issued by NIH pursuant to Section 301(d) of the Public Health Service Act (42 U.S.C. 241(d)), that protects the privacy of Human Subjects enrolled in the Protocol. With limited exceptions defined in 42 U.S.C. 241(d), the CoC protects from disclosure names or any information, documents, or biospecimens containing ISI collected under the Protocol conducted under this CTA.
“Clinical Research Site” means the NIH Clinical Center, their contractors, and Investigators at Bethesda, Maryland, USA where the Clinical Trial will be conducted in strict accordance with the Protocol.
“Clinical Study Report” in accordance with ICH E6 Section 1.13, is a written description of a Clinical Trial in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report. The Clinical Study Report contains information on results including reactogenicity, adverse events, immunogenicity, and other clinical or laboratory observations made with respect to the intervention employed in conducting the trial. A detailed description of the contents of a Clinical Trial Report is found in ICH E3 “Structure and Content of Clinical Study Reports.”
“Clinical Trial” is defined by the NIH as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. In this Agreement, Clinical Trial means the Clinical Trial for the Protocol.
“Completion of the Clinical Trial” means when all data analyses under the Protocol have been performed and the Clinical Study Report has been submitted to the FDA, thus completing the Clinical Trial.
“Confidential Information” means confidential scientific, proprietary, business, or financial information provided that Confidential Information does not include:
| (a) | information that is within the public domain prior to the time of the disclosure by the disclosing Party to the receiving Party or thereafter becomes within the public domain other than as a result of disclosure by the receiving Party or any of its representatives in violation of this Agreement; |
| (b) | information that was, on or before the date of disclosure, in the possession of the receiving Party without an obligation of confidentiality; |
| (c) | information that is acquired by the receiving Party from a third party not under an obligation of confidentiality; |
| (d) | information that is hereafter independently developed by the receiving Party without reference to the Confidential Information received from the disclosing Party; |
| (e) | information that the disclosing Party expressly authorizes the receiving Party to disclose; |
| (f) | information that is reasonably required by scientific standards for publication of the results of the Clinical Trial (including Clinical Trial methods and/or data) or any information that is necessary for other researchers to verify the results of the Clinical Trial; or |
| (g) | information that relates to potential hazards or cautionary warnings associated with the production, handling, or use of the Test Article. |
| Page 3 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
“Data and Safety Monitoring Board” (DSMB) is an independent group of experts that advises the NIAID and the Investigators. The primary responsibilities of the DSMB are to: (i) to periodically review and evaluate the accumulated data of the Clinical Trial for participant safety, Clinical Trial conduct and progress, and, when appropriate, efficacy; and (ii) to make recommendations to NIAID concerning the continuation, modification, or termination of the Clinical Trial.
“Data Coordination Center” (DCC) means an organization funded by the NIAID that receives, reviews, and performs data management tasks on the individual Human Subject Case Report Forms completed for this Clinical Trial. The Data Coordination Center for this Clinical Trial will be the LHD intramural staff using XXXX, CRIMSON, and Btris as well as REDCAP where appropriate.
“Distributor” is the NIAID contractor who will be distributing the Test Article to the Clinical Research Site. The Distributor for this Clinical Trial is [Insert Name].
“Effective Date” means the date of the last signature of the authorized representatives of the Parties executing this Agreement.
“Food and Drug Administration” (FDA) means the U.S. Food and Drug Administration.
“Government” means the federal government of the United States of America.
“Genome-Wide Association Study” (GWAS) means any study of genetic variation across the entire human genome that is designed to identify genetic associations with observable traits (such as blood pressure or weight) or the presence or absence of a disease or condition.
“Human Subject” as defined in 45 CFR 46 means a living individual about whom an Investigator conducting research obtains (l)data through intervention or interaction with the individual or (2) Identifiable Private Information.
“Identifiable Private Information” (IPI) means private information about a Human Subject from which the identity of the Human Subject is or may readily be ascertained. Regulations defining and governing this information include 45 C.F.R. Part 46 and 21 C.F.R. Part 50.
“Identifiable, Sensitive Information” (ISI) means, in accordance with the definition of 42 U.S.C. 241(d)(4), information that is about an individual and that is gathered or used during the course of research as described in 42 U.S.C. 241(d)(1)(A) through which an individual is identified, or that includes IPI, or for which there is at least a very small risk, as determined by current scientific practices or statistical methods, that some combination of the information, a request for the information, and other available data sources could be used to deduce the identity of an individual.
“Independent Safety Monitor” (ISM) is a physician or other expert who is independent of a study and readily available to review and recommend actions on adverse events and other safety issues.
“Informed Consent Form” means a signed and documented form in which each Human Subject voluntarily consents or confirms his or her willingness to participate in a particular clinical trial after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate. The informed consent form satisfies the requirements of ICH X0, 00 C.F.R. Part 46 and 21 C.F.R. Part 50.
| Page 4 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
“Institutional Review Board” (IRB) means, in accordance with 45 C.F.R. Part 46, Protection of Human Subjects (Revised November 13, 2001) and 21 C.F.R. Part 56, Subpart C: IRB Functions and Operations (as amended June 18, 1991), and other applicable regulations, an independent body comprising medical, scientific, and nonscientific members, whose responsibility is to ensure the protection of the rights, safety, and well-being of the Human Subjects involved in a Clinical Trial. It may also be referred to as an Independent Ethics Committee in accordance with ICH E6, Section 1.27.
“The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use” (ICH). ICH refers to one or all of the following requirements used throughout this Agreement:
| (a) | ICH E2F: “Development Safety Update Report”, including the latest finalized revision, if any. |
| (b) | ICH E3: “Structure and Content of Clinical Study Reports”, including the latest finalized revision, if any. |
| (c) | ICH E6: “Good Clinical Practice: Consolidated Guidance”, published in the Federal register (62 Federal Register 25692 (1997)), including the latest finalized revision. Also referred to as “FDA Good Clinical Practice Guidelines”. |
| (d) | ICH Q7: “Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients” published in the Federal register (66 Federal Register 49028-9 (2001)), including the latest finalized revision, if any. |
“Invention” means any invention or discovery that is or may be patentable or otherwise protected under 35 U.S.C., or any novel variety of plant which is or may be protectable under the Plant Variety Protection Act, 7 U.S.C. §§ 2321 et seq.
“Investigational New Drug Application” (IND) is filed in accordance with 21 C.F.R. Part 312 under which clinical investigation of a Test Article (an experimental drug or biologic) is performed in Human Subjects in the United States or intended to support a United States licensing action.
“Investigator” means, in accordance with 21 C.F.R. Part 312.3, an individual who actually conducts a clinical trial, that is, who directs the administration or dispensation of Test Article to a subject, and who assumes responsibility for studying Human Subjects, for recording and ensuring the integrity of research data, and for protecting the welfare and safety of Human Subjects. In this Agreement, “Investigator(s)” means the individual(s) identified as responsible for the conduct of the Clinical Trial at the Clinical Research Site.
“Investigator Brochure” (IB) means, in accordance with the definition in 21 C.F.R. Part 312.23(a)(5), a document containing information about the Test Article, including animal screening, preclinical toxicology, and detailed pharmaceutical data, including a description of possible risks and side effects to be anticipated on the basis of prior experience with the Test Article or related drugs, and precautions, such as additional monitoring, to be taken as part of the investigational use of the Test Article.
| Page 5 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
“Office of Human Research Protections” (OHRP) means the HHS office that oversees protection of human subjects from research risks under 45 C.F.R. Part 46 (the Common Rule).
“Party” means an entity entering into this Agreement, referred to individually as the “Party” and collectively as the “Parties”.
“Patent” means any issued United States patent, any international counterpart and any corresponding grant by a non-U.S. government in place of a patent.
“Protocol” means the formal, detailed description of the Clinical Trial to be performed as provided in Protocol 16-1-0032 for JSP191 the title of which is “High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease.” A Protocol describes the objective(s), design, methodology, statistical considerations, and organization of a clinical trial. For the purposes of this Clinical Trial, the term Protocol includes any and all associated documents, including informed consent forms, to be provided to Human Subjects and potential participants in the Clinical Trial. This Clinical Trial Agreement will be governed by the most recent version of the Protocol, and should this Agreement be executed prior to complete finalization of the Protocol, the last-dated version thereof will be considered to be incorporated by reference in place of any prior versions. In the event that there is a conflict between the terms of the Protocol and the terms of the Agreement, the terms of this Agreement will govern.
“Protocol Team” means the team, under the direction of NIAID, responsible for the development and management of the Protocol, evaluation of data, proposal of amendments, and all issues related to the Protocol or aspects of Protocol development and modification. The Protocol Team will include the representatives from the Company, if they wish to participate, the principal Investigators, representatives from the NIAID, and the persons involved with statistical and data analysis for the Clinical Trial. Participation on the Protocol Team will be as agreed by the Parties and will take into account any special requirements of the Protocol design.
Monitoring will be performed by the NIAID OCRPRO.
“Serious Adverse Event” or “Serious Suspected Adverse Reaction” means the definitions as stated in the Protocol.
“Sponsor” means, in accordance with the definition in 21 C.F.R. Part 312.3, an organization or individual who assumes legal responsibility for supervising or overseeing the Clinical Trial with Test Article, and is sometimes referred to as the “IND holder”. The Sponsor for the Protocol is NIAID.
“Sponsor Medical Monitor” or “SMM” is a Sponsor appointed physician with relevant expertise whose primary responsibility is to provide safety monitoring in a timely fashion. This is accomplished by review of adverse events, per protocol specification, with follow-up through resolution. The SMM evaluates individual and cumulative participant data when making recommendations regarding the safe continuation of the Clinical Trial.
“Suspected Adverse Reaction” means the definition as stated in the Protocol.
“Test Article” means, in accordance with 21 C.F.R. Part 50.3(j), any drug (including a biological product), medical device, food additive, color additive, electronic product, material or any other article subject to regulation under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301, et seq., Pub. L.No.75-717, 52 Stat. 1040 (1938), as amended. In this Agreement, JSP191 is/are collectively are referred to as the “Test Article”.
| Page 6 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
“Investigational Drug Delivery Errors” means the definition as stated in the Protocol.
“Unexpected/Unanticipated Problem” or “Unexpected/Unanticipated Suspected Problem” means the definitions as stated in the Protocol.
| 2. | CLINICAL RESEARCH SITE AND INVESTIGATORS |
| 2.1 | The NIAID will not knowingly utilize: |
| 2.1.1 | Any organization performing services in connection with this Clinical Trial that has been: |
| (i) | Debarred under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335a(a) and (b); or |
| (ii) | Suspended by the Office for Human Research Protections (OHRP) as a clinical research site under 45 C.F.R. Part 46; or |
| 2.1.2 | Any person convicted of a felony under federal law for conduct: |
| (i) | Relating to the development or approval, including, but not limited to, the process for development or approval, of any drug, product, medical device, New Drug Application (NDA), Pre-Market Application (PMA), 510(k), or IND, or similar application; or |
| (ii) | Otherwise relating to the regulation of any drug product or medical device under the FD&C Act; or |
| 2.1.3 | Any person performing services in connection with this Clinical Trial that has been disqualified as a clinical investigator under 21 C.F.R. Part 312.70; or |
| 2.1.4 | Any Investigator who is not qualified by training and experience as an appropriate expert to conduct the Clinical Trial, as required under 21 C.F.R. Part 312.53. |
| 2.2 | If either Party becomes aware that any organization or person involved in the Clinical Trial is debarred, threatened with debarment, disqualified, threatened with disqualification, or suspended, that Party will notify the other Party immediately. |
| 2.3 | The NIAID will conduct the Clinical Trial in accordance with good clinical practice, including as defined by the ICH and comply with all applicable U.S. and foreign government, state, and local laws, regulations, and guidelines. |
| 2.4 | The Company agrees that this Protocol will be conducted only at the Clinical Research Site. However, the Company can conduct, at its own expense and under its own IND, additional clinical trials with the Test Article, at non-NIAID-funded sites. The Company agrees to inform the NIAID in writing of any other clinical trials it may support for the use of the Test Article that would compete with this Clinical Trial for the same Human Subject population. NIAID acknowledges that the Test Article constitutes proprietary technology of the Company, and as such, Company may develop protocols that have similar elements in part to the Protocol. |
| Page 7 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 3. | INVESTIGATIONAL NEW DRUG APPLICATION SPONSORSHIP |
| 3.1 | IND. The NIAID will submit an IND covering the Protocol to the FDA. The IND will satisfy all of the requirements of the FDA. The Company will provide a letter granting the FDA permission to cross-reference the Company’s pertinent Drug Master File (DMF), New Drug Application (NDA), Biologics License Application (BLA), and/or INDs in support of the NIAID for the limited purpose of the IND, and in return, the NIAID will also provide a letter to the Company, if requested, granting the FDA permission to cross-reference the IND filed by the NIAID for this Clinical Trial. |
| 3.2 | Protocol Monitoring. The NIAID will be responsible for Clinical Research Site monitoring and quality assurance of all data in accordance with the clinical monitoring plan. Monitoring will be done in compliance with FDA Good Clinical Practice Guidelines (ICH) (E6). The NIAID will communicate any clinically significant findings from clinical monitors to the Company in a timely manner. |
| 3.3 | Safety Reporting |
| 3.3.1 | The NIAID will collect safety reports according to the procedure outlined in the Protocol. The NIAID will assume responsibility for the reporting of safety reports to the FDA and will provide copies of the reports to the Company. |
| (i) | NIAID will provide to the Company, all Serious Adverse Events within […***…] of discovery. The Company will provide analysis of similar events for expedited safety cases. |
For any safety report that meets all of the following criteria of (i) Serious (ii) Unexpected and (iii) Suspected Adverse Reaction, NIAID will provide to the Company, a completed copy of the safety report at the time the report is submitted to the FDA. NIAID will provide follow up information to Company at the time the follow up safety report is submitted to FDA. The reporting will be completed in the timeframes consistent with 21 CFR 312.32.
| (ii) | The NIAID will report all other Serious and non-serious Adverse Events to the FDA and to the Company on a timely basis consistent with 21 C.F.R. Part 312.33 and the Protocol. |
| 3.3.2 | As the manufacturer, the Company will, in a timely manner consistent with FDA requirements and during the term of this Clinical Trial, provide the NIAID with any material information it now has or may obtain in the future regarding the safety and/or the toxicity of Test Article. The NIAID will promptly transmit that information to all Investigators. |
| 3.3.3 | NIAID, as the sponsor of the clinical trial, can either provide FDA with a DSUR (Development Safety Update Report) and state certain information is not available to them or provide the information to the Company in the required timeframe so that it can be included in the Company’s DSUR. |
| Page 8 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 3.4 | Safety Monitoring. In accordance with NIH guidelines the Company and the NIAID agree that the following type(s) of safety monitoring is (are) necessary and appropriate for this Clinical Trial: |
| (a) | Independent Safety Monitor (ISM). If deemed necessary, the NIAID will appoint an ISM for the Clinical Trial; and |
| (b) | Data and Safety Monitoring Board (DSMB). A DSMB will continue to monitor the Clinical Trial, and the NIAID will notify the Company in advance of any DSMB review. The Company will receive the any identified safety concerns identified by the DSMB within […***…] of receiving that information. Prior to the Completion of the Clinical Trial, data and reports distributed for DSMB review will be used only for the purposes of the DSMB meeting and will be held in confidence by the DSMB. |
| 4. | FDA MEETINGS/COMMUNICATIONS |
| 4.1 | With respect to any discussions with the FDA involving data obtained from this Clinical Trial under NIAID’s IND, the NIAID, in consultation with the Company, will take the initiative in arranging meetings or conference calls with the FDA. Formal meetings with the FDA concerning the Clinical Trial design and/or data will be discussed and agreed upon in advance by the Company and the NIAID. The Company will have the right to participate in all formal meetings with the FDA. The Company agrees not to contact the FDA independent of the NIAID concerning this Clinical Trial. However, the Company may contact the FDA on separate product-related issues. |
| 4.2 | The Company will promptly notify NIAID of any FDA correspondence related to the Protocol that is received by the Company, or its Affiliates; any FDA enforcement actions directed toward the Company or its Affiliates related to the Test Article, including but not limited to: warning letters, seizures, recalls, injunctions/consent decrees, rejection of regulatory submissions or withdrawal of approval for a Test Article, criminal investigations, and proceedings to debar the Company or its Affiliates or individuals employed under a contract to the Company and/or its Affiliates. |
| 4.3 | The Company will also promptly notify NIAID of any action taken by the FDA regarding manufacturing of the Test Article that would impact the safety of Human Subjects in the Clinical Trial. |
| 5. | SUPPLY, DISTRIBUTION, AND USE OF TEST ARTICLE |
| 5.1 | Supply. |
| 5.1.1 | The Company will only supply the Test Article for the number of patients described in the clinical protocol to the NIAID […***…] and will use commercially reasonable efforts to supply the Test Article in quantities and conditions sufficient to complete the Protocol and on a schedule mutually agreed upon by the Parties to ensure a sufficient supply of unexpired Test Article. |
| 5.1.2 | The Company will be responsible for labeling the Test Article used in the Clinical Trial. |
| 5.2 | Distribution. |
| 5.2.1 | The Company will ship the Test Article to the Clinical Research Site as mutually agreed by the Parties. The Company will provide specific storage and/or shipping instructions for the Test Article to the NIAID, who will be responsible for adhering to them, as mutually agreed by the Parties. The Company warrants that any packaging for hazardous material provided by the Company meets Department of Transportation regulatory requirements for use at the Clinical Research Site. |
| Page 9 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 5.2.2 | The Test Article must be received by the Clinical Research Site in usable condition and accompanied by Material Safety Data Sheet (MSDS), specific storage and shipping instructions, stability and/or expiration dating information and the finally signed and dated Certificate of Analysis (COA) for each lot of Test Article sent. If the Company performs ongoing stability testing for each lot of Test Article sent, then the Company will also provide updated retest or expiration dates for those respective lots to NIAID in a timely manner. |
| 5.2.3 | If there is evidence that the Test Article that arrived at the Distributor or Clinical Research Site has not been maintained according to the defined shipping instructions or there is evidence of damage to the Test Article container or container closure system, NIAID will contact the Company to inform them of the condition of the received Test Article and to determine together with the Company whether the Test Article is usable or if it must be replaced. During the course of the Clinical Trial, the same process will be used whenever there is evidence that the Test Article has not been maintained according to the Company’s recommended storage conditions. If the Test Article must be replaced, the Company will replace it at […***…] to NIAID. |
| 5.3 | Use. |
| 5.3.1 | The NIAID will neither transfer the Test Article to parties other than the Distributor or the Clinical Research Site nor will the NIAID chemically modify, replicate, make derivatives of, or reverse engineer the Test Article unless required by the Protocol or mutually agreed in writing by the Parties. |
| 5.3.2 | The NIAID will request that the Investigators: |
| (i) | use the Test Article only in accordance with the Protocol and for no other purpose; |
| (ii) | not transfer the Test Article to any parties except the Company; and |
| (iii) | not chemically modify, replicate, make derivatives of, or reverse engineer the Test Article unless required by the Protocol or as mutually agreed to, in writing, by the Parties. |
| 5.4 | Investigator Brochure. The Company will provide a current Investigator Brochure for all applicable components of the Test Article, and any later revisions and addenda to the Investigator Brochure for the Test Article to NIAID, as mutually agreed by the Parties, and NIAID shall keep such components and other aforementioned materials in confidence in accordance with Section 11 (Confidential Information) of this Agreement. |
| 5.5 | Disposition of Unused Test Article. The NIAID will require the Clinical Research Site to destroy any unused or expired Test Article upon completion of the Protocol. |
| 5.6 | Warranty. The Company represents and warrants that the Test Article supplied shall be manufactured and released according to the principles of current Good Manufacturing Practice and when administered in accordance with Protocol it is suitable for human use. |
| 5.7 | Source. In the event the Company elects to terminate its development of Test Article for reasons other than safety or IRB approval withdrawal, without the transfer of its development efforts and obligations under this Agreement to another party acceptable to the NIAID within […***…] of discontinuation, then the Company will provide the NIAID with Test Article for all then-enrolled Human Subjects sufficient to complete the Clinical Trial in the manner described in the Protocol, but only to the maximum number of Human Subjects as identified in the Protocol at the time of Company’s notice of termination of its development of the Test Article. |
| Page 10 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 5.8 | Termination of Development. The Company hereby grants to the NIAID a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any invention which the Company has a right to license which the Company may have or obtain on Test Article, its manufacture, or on the process for use of Test Article, throughout the world, solely for medical research purposes related to Chronic Granulomatous Disease. This license will only become effective in the event the Company terminates its development of Test Article for reasons other than safety or IRB approval withdrawal, without the transfer of its development efforts to another party within […***…] of termination, and the NIAID elects to continue the development of Test Article. This provision will become null and void upon FDA approval of the Test Article indications and marketing of the Test Article by the Company. |
| 6. | PROTOCOL DEVELOPMENT |
| 6.1 | The Parties agree that enrollment in the Clinical Trial will not start until the version of the Protocol to be used has been reviewed in advance by the Protocol Team; approved (stipulations met/resolved) by the relevant IRB(s) and the NIAID in writing; and submitted to the FDA, the thirty (30) calendar day wait period has been satisfied and any FDA clinical hold issues have been responded to satisfactorily. The Protocol is a product of NIAID and will be deemed NIAID Confidential Information, as defined in Section 11 (Confidential Information) of this Agreement. |
The Parties agree that any alteration in or amendment to the Protocol must be accepted by the Protocol Team, and approved in writing by the relevant IRB(s) and the NIAID and submitted to the FDA, if appropriate, prior to such alteration or amendment becoming effective. The Company will have the right to review any amendments or alterations to the Protocol and NIAID will consider such comments in good faith in finalizing such amendments or alterations.
| 6.2 | The NIAID, through its contractors, will be responsible for performing the randomization. […***…] will determine who will have access to the randomization codes. |
| 7. | CASE REPORT FORM DEVELOPMENT |
The NIAID or its designee will be responsible for the development and subsequent revisions, if any, of the Case Report Forms with appropriate review and comment by the Protocol Team.
| 8. | HUMAN SUBJECTS PROTECTION |
| 8.1 | The NIAID and the Company recognize the principles of respect for persons, beneficence (including minimization of xxxxx and maximization of benefits), and justice as stated in the Belmont Report and will apply these principles in all research covered under this Agreement. The informed consent of each Human Subject participating in the Clinical Trial at the Clinical Research Site will be obtained prospectively using an IRB approved informed consent process. The informed consent document may be reviewed in advance by the Company and approved by the NIAID (which will consider in good faith any comments provided by the Company) and all appropriate Institutional Review Board (IRB). |
| Page 11 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 8.2 | The NIAID and the Company acknowledge and accept their responsibilities for protecting the rights and welfare of human research subjects set forth in 45 C.F.R. Part 46, Protection of Human Subjects (Revised November 13, 2001) and in a Certificate of Confidentiality issued by NIH in accordance with 42 U.S.C 241(d) of the Public Health Service Act. |
Therefore:
| 8.2.1 | Any ISI that Company receives from NIH is covered by a CoC and therefore all copies of ISI are immune from the legal process, and will not, without the consent of the Human Subject, be admissible as evidence or used for any purpose in any action, suit, or other judicial, legislative, or administrative proceeding. |
| 8.2.2 | The NIAID and the Company will maintain the confidentiality of ISI of Human Subjects collected under the Clinical Trial and protect the privacy of each of the individual Human Subjects in the Clinical Trial unless disclosure is required by law (e.g., as required by the Federal Food, Drug, and Cosmetic Act, or state laws requiring the reporting of communicable diseases to State and local health departments), excluding instances of disclosure in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding. Prior to making any permitted disclosures, Company will ensure that any recipient of ISI protected by a CoC is aware of its confidential nature and the requirement to comply with the CoC. |
| 8.2.3 | The NIAID and the Company may inspect, but not copy, Human Subjects’ medical records that might also include information not directly connected to this Clinical Trial. However, the NIAID and the Company agree that this information will remain confidential and will not be used for any purpose other than confirmation of Clinical Trial data. |
| 8.2.4 | The NIAID and the Company agree that neither Party will, nor will they allow the Clinical Research Sites to, include ISI that could lead to identification of individual Human Subjects in any release of data, reports or publications related to the Clinical Trial. The NIAID will require that the Investigators not include ISI that could lead to identification of individual Human Subjects in any release of data, reports or publications related to the Clinical Trial. |
| 8.2.5 | The NIAID and the Company agree that neither Party will, nor will they allow the Clinical Research Site to, use ISI about Human Subjects for any purpose not stated in the Protocol without the consent of the other Party and local site IRB approval. The NIAID will require that the Investigators not use IPI for any purpose not stated in the Protocol and informed consent document without the written consent of both Parties and appropriate IRB approval. |
| 8.2.6 | The NIAID and the Company agree to comply with the determinations of all IRBs overseeing this research. |
| 8.2.7 | Human Subject specimens and data provided, included but not limited to demographic, safety laboratory, safety data and drug exposure data, to the Company during and after the Clinical Trial will be coded. Unequivocally, neither IPI nor the key linking coded data to Human Subjects will be released to the Company. |
| Page 12 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 9. | DATA ANALYSIS AND MANAGEMENT; CLINICAL SPECIMENS AND ISOLATES |
| 9.1 | NIAID will be responsible for the data and scientific reporting of all results/data obtained from the Clinical Trial at the Clinical Research Site and the provision of applicable safety data and reports to Company. |
| 9.2 | The NIAID and/or the DCC will have responsibility for the data management: collection, entry, and quality control edits (with implied verifications and documentation) and analysis of data obtained from the Clinical Trial in accordance with the Protocol. |
| 9.3 | All data obtained from the Clinical Trial will be in the custody of the NIAID. However, other than the Company, its contractors and its designees, NIAID will not allow a third party to review or use the data obtained from the Clinical Trial for purposes of seeking regulatory approval unless the third party provides NIAID with written permission from the Company. NIAID agrees that the Company, its affiliates, its contractors and its designees may review and use the data obtained from the Clinical Trial for any legitimate business or regulatory purposes, including for purposes of seeking regulatory approval of the Test Article, with written notice to the NIAID. For avoidance of doubt, Company may provide any information regarding the Clinical Trial to governmental organizations including, but not limited to, the FDA, and the Securities and Exchange Commission (SEC) for all legitimate public health, regulatory, or business purposes, with written notice to the NIAID. |
| 9.4 | Upon completion of the data analyses, the NIAID will authorize transfer to the Company a copy of the complete data analysis set in a machine-readable format to be determined jointly by the Parties. If the Company requires that the data be provided to it in any customized format(s), the Company will […***…] associated with the customized data format(s). When applicable, compressed raw and intermediate genomics and/or other -omics data will be provided in industry/scientific community accepted data formats (e.g. FASTQ and/or BAM format for RNA-Sequence transcriptomics studies) at the time of data generation or transfer. Light-weight derived data such as gene expression values per sample will be provided in SAS format. |
| 9.5 | The NIAID is responsible for sending a final Clinical Study Report to the Company and the FDA as applicable, according to specified content, within a reasonable time after the dataset is locked, provided that the Company should have an opportunity to review for safety information and provide feedback to NIAID on the final Clinical Study Report for up to […***…]. |
| 9.6 | Subject to the right of the NIAID and the Investigators to publish the data from this Clinical Trial as set forth in Section 10 (Publications and Press Releases) of this Agreement, the Company has the right to utilize the data reports in its possession and all data obtained from this Clinical Trial for all legitimate business or regulatory purposes. The NIAID and/or the Company may provide any information regarding the Clinical Trial to governmental organizations including, but not limited to, the FDA, and the Securities and Exchange Commission (SEC) for all legitimate public health, regulatory or business purposes. Except for information related to regulatory or safety issues or under emergency circumstances where it is not practicable to do so and to the extent permitted by law, the NIAID will not release information regarding the Clinical Trial to governmental organizations provided that the Company should have an opportunity to review and provide feedback regarding safety information to NIAID on the publication for up to […***…]. |
| 9.7 | For applicable clinical trials, NIAID will post applicable primary and/or secondary endpoint results within […***…] of the last visit for primary and/or secondary end point evaluations. Therefore, any data that will be provided by the Company for primary or secondary outcomes (i.e. immunogenicity analysis) will be provided to NIAID no later than […***…] after the last visit of the last patient evaluated for the primary endpoint. |
| Page 13 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 9.8 | Clinical Specimens for Use in Protocol. All clinical specimens and isolates collected by the Investigators, or their staff, under this Clinical Trial will be and remain in the custody of NIAID. However, NIAID will provide Company with clinical specimens and isolates for analysis as stated in the Protocol. Company agrees to share with NIAID results derived from the analysis of clinical specimens and isolates. |
| 9.9 | During the Clinical Trial, the NIAID will provide the Company with aliquots of clinical specimens as needed for Protocol-related purposes only as requested by NIAID. However, nothing in this Agreement will be interpreted to transfer ownership of such clinical specimens to the Company. |
| 9.10 | Clinical Specimens for Use in Future Research. At the NIAID’s request, only when available and as permitted by the Informed Consent Form, provide the Company with some aliquots of clinical specimens, identified only by Clinical Trial subject number and accompanied by related encoded data for future studies. As stated in Section 8 (Human Subjects Protection) of this Agreement, the NIAID will provide to the Company only encoded data and encoded samples and will not provide the link between the code and the Human Subjects. However, nothing in this Agreement will be interpreted to transfer ownership of such samples to the Company. |
| 9.11 | Upon completion of the studies involving clinical specimens or upon the termination of this Agreement, whichever comes first, any unused clinical specimens and data derived from Human Subjects in the Company’s possession will be destroyed unless NIAID gives Company directions for disposing of the clinical specimens and data by another means. |
| 10. | PUBLICATIONS and PRESS RELEASES |
| 10.1 | Any publications based on the results of the Clinical Trial and originating from NIAID will conform to NIH publication policies. Unless requested otherwise by the Company, the NIAID will acknowledge the Company as the source of the Test Article in any NIAID publication resulting from the Clinical Trial. |
| 10.2 | Recognizing that employees of either Party may play an important role in the design, analysis, and interpretation of the findings of the Clinical Trial, each Party will include appropriate individuals from the other Party in the authorship of publications resulting from the Clinical Trial, in accordance with the International Committee of Medical Journal Editors authorship criteria. |
Each Party will provide the other Party with a copy of any abstract, or manuscript prior to submission for publication with sufficient time (i.e., for abstracts: at most […***…]; for manuscripts: at most […***…]) for review and comment. Each Party agrees that, following the receiving Party’s review of the abstract or manuscript for the maximum periods of time specified above, if no comment is received by the submitting Party, the submitting Party will be free to publish, present or use any Clinical Trial data. The receiving Party will maintain the proposed publication or public disclosure of the submitting Party as Confidential Information until publication or public disclosure by the submitting Party.
| 10.3 | If the Company requests additional time to file a patent application related to the publication: The publication or other disclosure may be delayed for up to […***…] for publications and […***…] for abstracts, upon written request by either Party as necessary to preserve U.S. or foreign patent or other intellectual property rights. |
| Page 14 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 10.4 | Each Party will provide a copy of any proposed press release to the other Party for review and comment at least […***…] in advance of proposed publication. Each Party agrees that, following the receiving Party’s review of the proposed press release for the maximum periods of time specified above, if no comment is received by the submitting Party, the submitting Party will be free to publish the press release. |
| 11. | CONFIDENTIAL INFORMATION |
| 11.1 | Either Party may disclose or receive Confidential Information under the terms and conditions of this Agreement. Each receiving Party will limit its disclosure and use of the disclosing Party’s Confidential Information to the amount necessary to conduct the Clinical Trial, and will place a confidentiality notice on all the Confidential Information. The disclosing Party will reduce confidential non-written communications to writing within […***…] of first disclosure. Each Party receiving Confidential Information agrees that any information so designated will be maintained as Confidential Information in accordance with this Agreement and used by it only for the purposes of the Clinical Trial. Any Party may object to the designation of information as Confidential by the other Party. |
| 11.2 | Unless expressly provided otherwise, neither Party will disclose, copy, reproduce or otherwise make the disclosing Party’s Confidential Information available to any other person or entity without the consent of the disclosing Party unless required by a court or administrative body of competent jurisdiction, the Freedom of Information Act (FOIA), 5 U.S.C. § 552, 45 C.F.R. Part 5, or other applicable laws and/or regulations to disclose the Confidential Information, except that the NIAID may disclose the Company’s Confidential Information to the Investigators and other parties, as required for the conduct of the Clinical Trial for purposes of the Clinical Trial. The NIAID will request such Investigators and such other parties receiving the Company’s Confidential Information to maintain the confidentiality of Confidential Information consistent with the terms of this Agreement. |
| 11.3 | Each Party will use the same level of care it uses with its own Confidential Information, but no less than a reasonable level of care, in maintaining the confidentiality of the other Party’s Confidential Information. While the NIAID will endeavor to control the distribution of the Protocol document itself, the Company acknowledges that some Government documents are available (with abstracts) to the public under the Freedom of Information Act. In addition, NIAID requires the posting of information on the XxxxxxxxXxxxxx.xxx registry of clinical studies, available through the NIH Website, consistent with the Food and Drug Administration Amendments Act of 2007, 000 XXXX. 000. |
| 11.4 | Consistent with the NIH policy for sharing data obtained in NIH supported or conducted GWAS, NIAID is required to submit GWAS data to a central NIH database (database of Genotypes and Phenotypes (dbGaP)) in accordance with NIH policy, where it may be accessed by Investigators. All data submitted is coded and de-identified. |
| 11.5 | Each Party agrees that the receiving Party is not liable for the disclosure of Confidential Information which, after notice to and consultation with the disclosing Party, the receiving Party determines may not be lawfully withheld, provided the disclosing Party has been given an opportunity to seek a court order to enjoin from disclosure. |
| 11.6 | Each Party’s obligation to maintain the confidentiality of Confidential Information will expire at the earlier of the date when the information is no longer Confidential Information as defined above or […***…] after the expiration or termination date of this Agreement. Either Party may request an extension to this term when necessary to protect Confidential Information relating to […***…]. This term does NOT apply to ISI, for which the obligation to maintain confidentiality will extend indefinitely. |
| Page 15 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 12. | INTELLECTUAL PROPERTY |
| 12.1 | Ownership of any Invention conceived as a consequence of conducting the Clinical Trial and involving the Test Article, will be determined under U.S. laws pertaining to intellectual property created in the course of federally funded research. Neither Party acquires by virtue of this Agreement any right, title, nor interest in or to any issued Patents or pending patent applications owned or controlled by the other Party. Nothing in this Agreement will be construed as granting any license or obligation to license any intellectual property owned by the Company to the NIAID with respect to the Test Article other than the limited right to use the Test Article for the performance of the Protocol in accordance with the terms of this Agreement. |
| 12.2 | NIAID Intellectual Property. |
| 12.2.1 | The Government will retain title to any Patent, pending patent applications or other intellectual property rights in Inventions conceived solely by NIAID employees in the course of the clinical research. |
| 12.2.2 | The NIAID agrees to notify the Company of any NIAID sole or joint Invention arising during the clinical research and to disclose it to the Company under an appropriate confidentiality agreement. The Company may apply for nonexclusive or exclusive license rights to any such patentable Invention made by NIAID employees that might arise during the clinical research and the NIH will consider the Company’s application for a nonexclusive or exclusive license consistent with 37 C.F.R. Part 404. The NIAID agrees that if the Parties enter into a Clinical Cooperative Research and Development Agreement (Clinical CRADA) that relates to the subject matter of this Agreement it will include terms to be negotiated then that provide to the Company (i) a non-exclusive, royalty-free, internal-use research license and (ii) a first and exclusive option for Company to negotiate for a royalty-bearing exclusive license (or, at Company’s election, non-exclusive license) to any sole or joint Invention for commercial use, in all cases subject to and consistent with 37 C.F.R. Part 404. |
| 12.3 | Company Intellectual Property. The Company will retain title to any Patents, pending patent applications, or other intellectual property rights in Inventions conceived by its employees during the course of the clinical research. |
| 12.4 | Joint NIAID-Company Intellectual Property. The NIAID and the Company will have joint intellectual property rights in Inventions conceived jointly by their employees during the course of the clinical research. Company may receive a non-exclusive or exclusive license to the NIAID rights in such Inventions in accordance with the 37 CFR 404 and Section 12.2.2. |
| 13. | FORCE MAJEURE |
Neither Party will be liable for any unforeseeable event beyond its reasonable control not caused by the fault or negligence of such Party, which causes such Party to be unable to perform its obligations under this Agreement, and which it has been unable to overcome by the exercise of due diligence. In the event of the occurrence of such a force majeure event, the Party unable to perform will promptly notify the other Party. It will further use its best efforts to resume performance as quickly as possible and will suspend performance only for such period of time as is necessary as a result of the force majeure event.
| Page 16 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 14. | LIABILITY, INDEMNIFICATION, INSURANCE, & RESEARCH RELATED INJURY |
| 14.1 | Liability. In view of the Anti-Deficiency Act, 31 U.S.C § 1341, NIAID cannot agree to indemnify the Company for its losses. Each Party will be liable for the losses, claims, damages, or liabilities that it incurs as a result of its activities under this Agreement except that the NIAID, as an agency of the Government, assumes liability only to the extent provided under the Federal Tort Claims Act, 28 U.S.C. Ch. 171. |
| 14.2 | Indemnification. Subject to Term 14.5, the Company will defend, indemnify and hold harmless NIAID, and its grantees and their respective employees (“Indemnitee(s)”) from any and all liabilities, damages, losses, claims, action, suits and expenses, including attorneys’ fees and court costs (collectively “Claims”) to the extent caused by the administration or use of the Test Article in the Clinical Trial. The Company’s control over the defense and settlement of any claim against NIAID will be subject to the consent of NIAID and the Department of Justice, and such consent may not be unreasonably withheld. The Indemnitee(s) will at all times have the right to fully participate in the defense of any Claim at their own expense and for their own account, subject to the foregoing sentence. Company’s obligation to so indemnify Indemnitee(s) will only apply if each of the following conditions is met: |
| 14.2.1 | The Claim was not proximately caused by the Indemnitee(s)’ failure to conduct the Clinical Trial in accordance with the Protocol, other written instructions provided to the NIAID by the Company, and this Agreement; |
| 14.2.2 | The Claim was not caused by the negligence, recklessness, or willful misconduct of any Indemnitee or violation of law or regulation or a material breach of this Agreement by NIAID, provided that any action properly taken by the Indemnitee in compliance with the Protocol or written instructions from the Company will be deemed, for purposes of this condition, not to be negligent, and provided further that if a Claim is jointly caused by the negligence of any Indemnitee and the administration or use of the Test Article, then Company will provide defense and indemnification solely to the extent the Claim was caused by the administration of the Test Article in accordance with the Protocol, other written instructions provided to the NIAID by the Company, and this Agreement; |
| 14.2.3 | The Claim was not caused by a material alteration in or amendment to the Protocol that was not approved in writing by Company; |
| 14.2.4 | The Company is promptly notified of the Claim; |
| 14.2.5 | The Indemnitee(s) fully cooperates with the Company and its legal representatives in the investigation and defense of the Claim. |
| 14.3 | Insurance. The Company represents and warrants that it will maintain during the term of this Agreement or the Protocol, whichever is longer, a liability insurance policy or a program of insurance or self-insurance at levels sufficient to support the indemnification obligations assumed under this Agreement and to cover the costs of medical care required to treat or stabilize adverse reactions attributable to the Test Article suffered by Human Subjects who received Test Article in accordance with the approved Protocol. Upon request, the Company will provide evidence of its insurance or self-insurance to NIAID. |
| Page 17 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 14.4 | Human Subject Injury or Illness Attributable to the Test Article. The Company will pay the reasonable cost of medical care required by Human Subjects for illness or injury attributable to the Test Article, to the extent such costs are (i) not covered by the Human Subject’s medical or hospital insurance or by third party or governmental programs providing such coverage, and (ii) not the result of the Human Subject’s pre-existing abnormal medical condition or underlying disease or the NIAID’s gross negligence. For purposes of this determination and the Company’s obligation under this Agreement, “attributable” means that the receipt of the Test Article and the Clinical Trial Human Subject’s illness or injury are reasonably related in time, and the illness or injury is more likely explained by the receipt of the Test Article than any other cause. The payment or offer of payment of any amount by the Company on behalf of a Human Subject or his or her healthcare insurer or other third party payer under this Section is not an admission of fault or liability by any one or more of (a) the Government or any agency thereof; or (b) the Company, its employees or agents, and any such payment or offer of payment will not be considered a waiver of any defense or other legal right by any of the foregoing in any legal, administrative or similar proceeding. |
| 14.5 | Limitation on Liability. Each party shall be liable for such loss, claim, damage, or liability that said party incurs as a result of its activities under this Agreement, except that NIH, as an agency of the United States, assumes liability only to the extent provided under the Federal Tort Claims Act, 28 U.S.C. §§ 2671 et seq. In no event shall Company be liable to the NIAID or any party for any special incidental or consequential damages arising out of or relating to this Agreement, or the subject matter hereof, however caused and whether such claim is based in contract, tort (including negligence and strict liability) or otherwise, even if authorized representative of Company is advised of the possibility of such damages. Except for Company’s indemnification obligations hereunder, the total, cumulative liability of Company arising out of or related to this Agreement shall not exceed […***…] U.S. dollars ($[…***…]). |
| 14.6 | Disclaimer. Except as specifically stated in Section 5.6, the Test Article is provided “AS IS” and “WITH ALL FAULTS”, and the Company expressly disclaims any warranties, express or implied, of any kind, including any implied warranties of merchantability, fitness for a particular purpose or noninfringement of intellectual property rights of third parties. |
| 15. | DISPUTES |
Any dispute arising under this agreement that is not disposed of by Agreement of the Parties will be submitted jointly to the signatories of this Agreement. If the signatories are unable to jointly resolve the dispute within […***…] after notification thereof, the dispute will be referred to the Director of NIAID (or his/her designee) and an appropriate authorized representative of the Company for resolution. If the Director of NIAID (or his/her designee) and the authorized representative of the Company are unable to jointly resolve the dispute within […***…], either Party may pursue any and all administrative or judicial remedies that may be available.
| 16. | INDEPENDENT CONTRACTORS |
In the performance of all work under this Agreement, neither Party is authorized or empowered to act as agent for the other for any purpose and will not, on behalf of the other Party, enter into any contract, warranty, or representation as to any matter. Neither Party will be bound by the acts of the other Party.
| Page 18 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 17. | NON-ENDORSEMENT |
By entering into this Agreement, the NIAID does not directly or indirectly endorse any product or service provided, or to be provided, by the Company. The Company will not in any way state or imply that this Agreement is an endorsement of those product(s) or service(s) by the Government or any of its organizational units or employees. However, the Company may reference or use publications and reports based on the Clinical Trial for legitimate business and regulatory purposes.
| 18. | AMENDMENTS |
Modifications to this Agreement will not be effective unless made in writing, as mutually agreed, and signed by a duly authorized representative of each Party.
| 19. | SURVIVABILITY |
The provisions of Sections 2 (Clinical Research Site and Investigators), 3 (Investigational New Drug Application Sponsorship), 4 (FDA Meetings/Communications), 5 (Supply, Distribution, and Use of Test Article), 8 (Human Subjects Protection), 9 (Data Analysis and Management; Clinical Specimens and Isolates), 10 (Publications and Press Releases), 11 (Confidential Information), 12 (Intellectual Property), 14 (Liability, Indemnification, Insurance, and Research Related Injury), 17 (Non-Endorsement), this Section 19 (Survivability) and sub-Section 23.4 will, in each case, survive the expiration or earlier termination of this Agreement.
| 20. | ENTIRE AGREEMENT AND SEVERABILITY |
This Agreement constitutes the entire Agreement and understanding of the Parties with respect to the subject matter hereof and supersedes any prior understanding or written or oral Agreement. The provisions of this Agreement are severable and, in the event that any provision of this Agreement will be determined to be invalid or unenforceable under any controlling body of law, such determination will not in any way affect the validity and enforceability of the remaining provisions of this Agreement.
| 21. | ASSIGNMENT |
Neither this Agreement nor any rights or obligations of any Party hereunder will be assigned or otherwise transferred by either Party without the prior written permission of the other Party, provided, however, that the Company may assign this Agreement at any time without the consent of NIAID to any Affiliate of Company or to any third party in connection with a sale of all or substantially all of the business or assets of Company that relate to this Agreement to such third party.
| 22. | APPLICABLE LAW |
This Agreement will be construed in accordance with Federal law as applied by the Federal courts of the District of Columbia.
| 23. | TERM AND TERMINATION |
| 23.1 | Unless terminated sooner in accordance with this Section 23, this Agreement will expire upon receipt of the final study report by the Company. |
| 23.2 | The Parties may terminate this Agreement at any time by mutual written consent. |
| Page 19 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
| 23.3 | Either Party may unilaterally terminate this Agreement at any time by giving written notice at least thirty (30) calendar days prior to the desired termination date. |
| 23.4 | If this Agreement is terminated prior to completion of the Protocol, the Protocol will be completed if medically or ethically appropriate. In that event, each enrolled Human Subject will be followed through the period outlined in the Protocol and the Company will use its best commercial efforts to supply enough Test Article to complete the Protocol for the maximum number of Human Subjects identified in the approved Protocol at the time of the notice of termination. |
| 23.5 | In the event the Company elects to terminate its obligations under the terms of this Agreement, due to an unexpected dissolution, the Company must notify NIAID within at least thirty (30) calendar days of the dissolution; and use its best efforts to provide NIAID with the resources necessary to complete the Protocol in addition to the terms of Section 5 above. |
| 24. | NOTICES |
Any notice or report required under the terms of this Agreement will be sent to the other Party at the addresses indicated below. Any notice will be deemed to be effective when delivered to the other Party by courier, registered mail (with return receipt), via facsimile, Portable Document Format (PDF), or email followed by conformational hard copies when requested.
For the Company:
For legal matters: […***…]
Jasper Therapeutics, Inc.
0000 Xxxxxx Xxxxxxx, Xxx. 000
Xxxxxxx Xxxx, XX 00000
[…***…]
For technical/clinical matters:
[…***…]
Jasper Therapeutics, Inc.
0000 Xxxxxx Xxxxxxx, Xxx. 000
Xxxxxxx Xxxx, XX 00000
For the NIAID:
For Agreement term matters:
NIAID-TTIPO, Attn. […***…]
0000 Xxxxxxx Xxxx, […***…]
Xxxxxxxxx, Xxxxxxxx 00000 XXX
Ph: […***…] / Fax: […***…]
For technical/clinical matters:
[…***…]
[…***…], NIH-NIAID-LCIM
[…***…]
00 Xxxxxx Xxxxx
Xxxxxxxx, XX 00000
Ph: […***…] / Fax: […***…]
SIGNATURES BEGIN ON THE NEXT PAGE
| Page 20 of 21 |
| NIAID Intramural Clinical Trial Agreement (Clinical Center) | NIAID Xxxxxxxx # 00-X-0000 |
| Jasper Therapeutics NIAID |
If the Company agrees with the terms of this Agreement for the Clinical Trial in accordance with the Protocol designated as Protocol No. 16-1-0032 for JSP191 the title of which is “High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease,” please have an authorized representative sign below.
| FOR NIAID: | ||
| /s/ Xxxxx X. Xxxxxx -S | 5/3/2021 | |
| Xxxxxx X. Xxxxxxx, M.D. | Date | |
| Director, Division of Intramural Research | ||
| National Institute of Allergy and Infectious Diseases |
||
| National Institutes of Health | ||
| Department of Health and Human Services | ||
| FOR COMPANY: | ||
| /s/ Xxxx Xxxxx | 5/7/21 | |
| (Signature) | Date | |
| Xxxx Xxxxx | ||
| Chief Financial Officer | ||
| Jasper Therapeutics, Inc. | ||
| 0000 Xxxxxx Xxxxxxx, Xxx. 000 | ||
| Xxxxxxx Xxxx, XX 00000 |
Page 21 of 21
